Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
News for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) centers on its role as a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated skin diseases. Company announcements frequently highlight developments in its ZORYVE (roflumilast) topical franchise for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, along with updates on its broader immuno-dermatology pipeline.
Investors and clinicians following ARQT news can expect detailed coverage of regulatory milestones, such as U.S. Food and Drug Administration (FDA) approvals and supplemental new drug application (sNDA) acceptances for new age groups and indications. Releases describe label expansions for ZORYVE cream and foam, including approvals for pediatric atopic dermatitis and seborrheic dermatitis, and FDA review timelines for potential new pediatric plaque psoriasis indications.
Arcutis also reports on clinical trial progress and data presentations. Recent news includes completion of enrollment in pediatric studies like INTEGUMENT-INFANT, publication of long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, and new Phase 3 analyses showing improvements in itch, sleep disruption, and long-term disease control with ZORYVE cream 0.15% and 0.05% in atopic dermatitis.
Financial and corporate updates form another key news category. The company issues quarterly earnings releases detailing net product revenue for ZORYVE, outlines strategies for sustainable growth, and provides guidance on future net product sales. Additional items include inducement equity grants, participation in investor conferences, and board-level changes disclosed via press releases and Form 8-K filings.
News flow also covers pipeline and strategic priorities, such as Phase 2 proof-of-concept trials of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and early clinical development plans for ARQ-234, a CD200 receptor checkpoint agonist being developed as a potential biologic for atopic dermatitis. Together, these updates give readers insight into Arcutis’ commercial performance, regulatory trajectory, and ongoing research in immuno-dermatology.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has been added to the NASDAQ Biotechnology Index effective December 21, 2020. This inclusion, based on criteria such as market capitalization and trading volume, aligns Arcutis with prominent biotech entities, enhancing its visibility and credibility in the market. As a late-stage biopharmaceutical company, Arcutis specializes in developing treatments for immune-mediated dermatological conditions, with a robust pipeline of four novel drug candidates, including topical roflumilast aimed at addressing multiple skin disorders.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced significant progress in its immuno-dermatology platform during its Virtual Investor Day on December 9, 2020. The company showcases a robust pipeline with 4 development programs targeting 7 dermatological diseases, including Phase 2 and Phase 3 initiatives. Potential U.S. market sales could reach $3 billion to $8 billion by 2030. Key products include topical roflumilast for conditions like psoriasis and atopic dermatitis, demonstrating strong safety and efficacy. The company aims to leverage its innovative strategies and continued clinical advancements.
Arcutis Biotherapeutics has completed the 8-week treatment period for its pivotal Phase 3 clinical trials, DERMIS-1 and DERMIS-2, evaluating ARQ-151 (topical roflumilast cream) for plaque psoriasis. Approximately 8.6 million U.S. patients suffer from this condition. Topline data is expected in Q1 2021, with a potential NDA submission to the FDA by year-end. The cream is positioned as a ‘Best in Class’ topical PDE4 inhibitor, promising enhanced outcomes without compromising safety. Previous Phase 2 studies support its chronic use.
Arcutis Biotherapeutics (Nasdaq: ARQT) will host a virtual Investor Day on December 9, 2020, from 11:00 AM to 1:00 PM EST. The event will highlight the company's innovative immune-dermatology product development platform and its promising pipeline of drug candidates aimed at treating various skin conditions. Presentations will include insights from Arcutis' Senior Leadership Team and dermatologist Zoe Diana Draelos, M.D. Registration for the event is available online, and a live audio webcast will be accessible on the Investor Relations section of the Arcutis website.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) reported positive outcomes from a long-term safety study of its ARQ-151 topical cream for treating plaque psoriasis. The study demonstrated favorable safety and tolerability, with only 3.6% of patients experiencing treatment-related adverse events over a span of 52 to 64 weeks. Notably, 44.8% of subjects achieved an Investigator Global Assessment (IGA) of clear or almost clear at week 52. The company anticipates pivotal Phase 3 data in Q1 2021, bolstering its commitment to develop effective therapies for unmet dermatological needs.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced positive results from its Phase 2b trial of roflumilast foam for scalp psoriasis, demonstrating significant improvement on primary and secondary endpoints. The foam showed a 59.1% success rate on the primary endpoint versus 11.4% for the vehicle (p0.0001). Additionally, 71% of participants experienced meaningful itch reduction. The safety profile was favorable, with low discontinuation rates. With approximately 40% of psoriasis patients affected by scalp involvement, roflumilast foam is positioned as a potential 'Best in Class' treatment option.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that CEO Frank Watanabe will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020 at 12:20 p.m. PST. The presentation will focus on Arcutis’ developments in immuno-dermatology, highlighting its innovative therapies targeting unmet needs in skin diseases. The event will be webcast, accessible via Arcutis’ website, with a replay available for 30 days post-conference. Arcutis is advancing treatments for conditions such as plaque psoriasis and atopic dermatitis.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported third-quarter results on November 5, 2020, revealing a net loss of $38.2 million, equating to $1.01 per share. The company holds over $300 million in cash and equivalents, ensuring operational funding into 2022. Upcoming pivotal Phase 3 data for roflumilast cream in plaque psoriasis is expected in Q1 2021. Positive Phase 2 data for seborrheic dermatitis strengthens its pipeline, targeting a market of over 20 million patients in the U.S. R&D expenses surged to $32.7 million, largely due to new clinical trials.
Arcutis Biotherapeutics (Nasdaq: ARQT) has appointed Terrie Curran to its Board of Directors, effective Nov. 2, 2020, following the resignation of Alexander Asam. Curran brings over 20 years of experience in biopharmaceuticals and will aid in commercialization as Arcutis prepares for pivotal Phase 3 trial data and potential NDA submission for its lead product, topical roflumilast. This treatment aims to set a new standard for several inflammatory dermatological conditions. The company anticipates growth and innovation under Curran's leadership.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced positive results from its Phase 2 studies of roflumilast cream for plaque psoriasis and atopic dermatitis. The Phase 2b study demonstrated significant reduction in itch severity and related sleep loss, with 63% of patients achieving clinically meaningful itch reduction by week 12. In atopic dermatitis, although the primary endpoint did not reach statistical significance, notable improvements were recorded. Both studies reported roflumilast cream as safe and well-tolerated, supporting its potential as a leading topical treatment option.